MX2023006566A - Sistemas crispr tipo v clase 2 diseñados por ingeniería. - Google Patents
Sistemas crispr tipo v clase 2 diseñados por ingeniería.Info
- Publication number
- MX2023006566A MX2023006566A MX2023006566A MX2023006566A MX2023006566A MX 2023006566 A MX2023006566 A MX 2023006566A MX 2023006566 A MX2023006566 A MX 2023006566A MX 2023006566 A MX2023006566 A MX 2023006566A MX 2023006566 A MX2023006566 A MX 2023006566A
- Authority
- MX
- Mexico
- Prior art keywords
- type
- crispr systems
- engineered class
- engineered
- class
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121196P | 2020-12-03 | 2020-12-03 | |
| US202163162346P | 2021-03-17 | 2021-03-17 | |
| US202163208855P | 2021-06-09 | 2021-06-09 | |
| PCT/US2021/061673 WO2022120095A1 (en) | 2020-12-03 | 2021-12-02 | Engineered class 2 type v crispr systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006566A true MX2023006566A (es) | 2023-08-07 |
Family
ID=80050633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006566A MX2023006566A (es) | 2020-12-03 | 2021-12-02 | Sistemas crispr tipo v clase 2 diseñados por ingeniería. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20240026385A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4256054A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7882533B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230128289A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021392719B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3201258A1 (cg-RX-API-DMAC7.html) |
| CL (2) | CL2023001594A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2616584B (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023006566A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20231178A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI922538B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022120095A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202113253SA (en) | 2019-06-07 | 2021-12-30 | Scribe Therapeutics Inc | Engineered casx systems |
| US12551560B2 (en) | 2019-09-09 | 2026-02-17 | Scribe Therapeutics Inc. | Compositions and methods for use in immunotherapy |
| WO2021113763A1 (en) | 2019-12-06 | 2021-06-10 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of rhodopsin |
| AU2021392719B2 (en) | 2020-12-03 | 2025-08-14 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| WO2022261150A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
| IL311610A (en) | 2021-09-21 | 2024-05-01 | Scribe Therapeutics Inc | Engineered CASX suppressor systems |
| CA3257824A1 (en) | 2022-06-02 | 2023-12-07 | Scribe Therapeutics Inc. | MODIFIED TYPE V, CLASS 2 CRISPR SYSTEMS |
| WO2023235888A2 (en) | 2022-06-03 | 2023-12-07 | Scribe Therapeutics Inc. | COMPOSITIONS AND METHODS FOR CpG DEPLETION |
| EP4536819A1 (en) | 2022-06-07 | 2025-04-16 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| WO2023240027A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Particle delivery systems |
| CN119998446A (zh) | 2022-06-07 | 2025-05-13 | 斯克里贝治疗公司 | 用于靶向pcsk9的组合物和方法 |
| EP4536286A1 (en) | 2022-06-08 | 2025-04-16 | Scribe Therapeutics Inc. | Aav vectors for gene editing |
| WO2023240157A2 (en) | 2022-06-08 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of dmd |
| CN116676291B (zh) * | 2022-08-22 | 2024-02-27 | 华中农业大学 | 核酸内切酶Genie scissor及其介导的基因编辑系统 |
| WO2024206676A1 (en) | 2023-03-29 | 2024-10-03 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of lpa |
| WO2024206620A1 (en) | 2023-03-29 | 2024-10-03 | Scribe Therapeutics Inc. | Messenger rna encoding casx |
| WO2024206555A1 (en) | 2023-03-29 | 2024-10-03 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| TW202444914A (zh) | 2023-03-29 | 2024-11-16 | 美商斯奎柏治療公司 | 抑制子融合蛋白系統 |
| CN122139028A (zh) * | 2023-08-25 | 2026-06-02 | 国立大学法人 东京大学 | 工程化的蛋白质 |
| JP7560818B1 (ja) | 2023-08-25 | 2024-10-03 | 株式会社キュライオ | エンジニアリングされたタンパク質 |
| WO2025072293A1 (en) | 2023-09-27 | 2025-04-03 | Scribe Therapeutics Inc. | Optimized mrnas encoding casx proteins |
| WO2025240940A1 (en) | 2024-05-17 | 2025-11-20 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of apolipoprotein c3 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| ATE219660T1 (de) | 1994-09-30 | 2002-07-15 | Inex Pharmaceuticals Corp | Mittel zum einbringen polyanionischer materialien in zellen |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5695937A (en) | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| CA2597724A1 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
| EP2279254B1 (en) | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
| US9221902B2 (en) | 2008-11-07 | 2015-12-29 | Fabrus, Inc. | Combinatorial antibody libraries and uses thereof |
| WO2010075303A1 (en) | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| ES2613498T3 (es) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos |
| EA022786B1 (ru) | 2009-07-31 | 2016-03-31 | Этрис Гмбх | Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков |
| US9580714B2 (en) | 2010-11-24 | 2017-02-28 | The University Of Western Australia | Peptides for the specific binding of RNA targets |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| CA2953341C (en) | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| CA2969619A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| EP3247328B1 (en) | 2015-01-21 | 2026-01-07 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| CA3012631A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| HUE067372T2 (hu) | 2015-06-29 | 2024-10-28 | Acuitas Therapeutics Inc | Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására |
| WO2017064546A1 (en) * | 2015-09-24 | 2017-04-20 | Crispr Therapeutics Ag | Novel family of rna-programmable endonucleases and their uses in genome editing and other applications |
| CN116814590A (zh) | 2015-10-22 | 2023-09-29 | 布罗德研究所有限公司 | Vi-b型crispr酶和系统 |
| CN108368028B (zh) | 2015-10-28 | 2021-09-03 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
| EP3374494A4 (en) | 2015-11-11 | 2019-05-01 | Coda Biotherapeutics, Inc. | CRISPR COMPOSITIONS AND METHODS OF USE THEREOF FOR GENE THERAPY |
| EP3390624A4 (en) | 2015-12-18 | 2019-07-10 | The Regents of The University of California | Modified site-directed modifying polypeptides and methods of use thereof |
| US9896696B2 (en) | 2016-02-15 | 2018-02-20 | Benson Hill Biosystems, Inc. | Compositions and methods for modifying genomes |
| EP3468612A1 (en) | 2016-06-09 | 2019-04-17 | CureVac AG | Hybrid carriers for nucleic acid cargo |
| WO2017212007A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Cationic carriers for nucleic acid delivery |
| CN109688820B (zh) | 2016-06-24 | 2023-01-10 | 科罗拉多州立大学董事会(法人团体) | 用于生成条形码化组合文库的方法 |
| CN106057265B (zh) * | 2016-07-08 | 2017-11-17 | 广东省稀有金属研究所 | 一种从萃取镧的废水中除放射性的方法 |
| WO2018035250A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Methods for identifying class 2 crispr-cas systems |
| JP2019532644A (ja) | 2016-09-30 | 2019-11-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Rna誘導型核酸修飾酵素及びその使用方法 |
| US9982267B2 (en) | 2016-10-12 | 2018-05-29 | Feldan Bio Inc. | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
| EP3568470B1 (en) | 2017-01-10 | 2022-07-06 | Christiana Care Health Services, Inc. | Methods for in vitro site-directed mutagenesis using gene editing technologies |
| US20190367924A1 (en) | 2017-02-17 | 2019-12-05 | Temple University - Of The Commonwealth System Of Higher Education | Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5 |
| MX2019011215A (es) | 2017-03-24 | 2020-02-12 | Curevac Ag | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. |
| US11773409B2 (en) | 2017-04-21 | 2023-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | CRISPR/Cas 9-mediated integration of polynucleotides by sequential homologous recombination of AAV donor vectors |
| WO2019084148A1 (en) | 2017-10-25 | 2019-05-02 | Monsanto Technology Llc | TARGETED RNA GUIDED ENDONUCLEASE ENDONUCLEASE ACTIVITY IN EUKARYOTES |
| US10253365B1 (en) | 2017-11-22 | 2019-04-09 | The Regents Of The University Of California | Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs |
| EP3758714A4 (en) | 2018-02-27 | 2021-12-01 | The University of North Carolina at Chapel Hill | METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN'S SYNDROME |
| US20200224160A1 (en) | 2018-02-27 | 2020-07-16 | Sorrento Therapeutics, Inc. | Process for dna integration using rna-guided endonucleases |
| US12522811B2 (en) | 2018-05-01 | 2026-01-13 | The Children's Medical Center Corporation | Enhanced BCL11A RNP / CRISPR delivery and editing using a 3XNLS-CAS9 |
| US20210139892A1 (en) | 2018-07-05 | 2021-05-13 | The Regents Of The University Of California | Compositions and methods for delivery of rna to a cell |
| US20210284981A1 (en) | 2018-07-24 | 2021-09-16 | The Regents Of The University Of California | Rna-guided nucleic acid modifying enzymes and methods of use thereof |
| EP3841205A4 (en) | 2018-08-22 | 2022-08-17 | The Regents of The University of California | VARIANT TYPE V CRISPR/CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF |
| SG11202113253SA (en) | 2019-06-07 | 2021-12-30 | Scribe Therapeutics Inc | Engineered casx systems |
| WO2020247883A2 (en) | 2019-06-07 | 2020-12-10 | Scribe Therapeutics Inc. | Deep mutational evolution of biomolecules |
| WO2021007177A1 (en) | 2019-07-08 | 2021-01-14 | The Regents Of The University Of California | Variant type v crispr/cas effector polypeptides and methods of use thereof |
| AU2020324386B2 (en) | 2019-08-02 | 2026-04-23 | Monsanto Technology Llc | Methods and compositions to promote targeted genome modifications using HUH endonucleases |
| EP4028522A1 (en) | 2019-09-09 | 2022-07-20 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of sod1 |
| US12551560B2 (en) | 2019-09-09 | 2026-02-17 | Scribe Therapeutics Inc. | Compositions and methods for use in immunotherapy |
| IL292571A (en) | 2019-10-28 | 2022-06-01 | Targetgene Biotechnologies Ltd | Pam-reduced and pam-abolished cas derivatives compositions and uses thereof in genetic modulation |
| WO2021113772A1 (en) | 2019-12-06 | 2021-06-10 | Scribe Therapeutics Inc. | Particle delivery systems |
| WO2021113763A1 (en) | 2019-12-06 | 2021-06-10 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of rhodopsin |
| EP4069846A1 (en) | 2019-12-07 | 2022-10-12 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of htt |
| JP2023510352A (ja) | 2020-01-10 | 2023-03-13 | スクライブ・セラピューティクス・インコーポレイテッド | Pcsk9の標的化のための組成物および方法 |
| MX2022011460A (es) | 2020-03-18 | 2022-12-15 | Scribe Therapeutics Inc | Composiciones y métodos para el direccionamiento de c9orf72. |
| WO2022119957A1 (en) | 2020-12-02 | 2022-06-09 | The Regents Of The University Of California | Crispr-cas effector polypeptides and methods of use thereof |
| EP4255502A4 (en) | 2020-12-03 | 2025-07-16 | Scribe Therapeutics Inc | COMPOSITIONS AND METHODS FOR TARGETING BCL11A |
| AU2021392719B2 (en) | 2020-12-03 | 2025-08-14 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| KR20230129395A (ko) | 2020-12-09 | 2023-09-08 | 스크라이브 테라퓨틱스 인크. | 유전자 편집을 위한 aav 벡터 |
| CN117083385A (zh) | 2021-03-26 | 2023-11-17 | 特定生物制品公司 | 用双裂解内切核酸酶靶向致癌突变 |
| WO2022261150A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
| IL311610A (en) | 2021-09-21 | 2024-05-01 | Scribe Therapeutics Inc | Engineered CASX suppressor systems |
| EP4405490A2 (en) | 2021-09-23 | 2024-07-31 | Scribe Therapeutics Inc. | Self-inactivating vectors for gene editing |
| CA3257824A1 (en) | 2022-06-02 | 2023-12-07 | Scribe Therapeutics Inc. | MODIFIED TYPE V, CLASS 2 CRISPR SYSTEMS |
| CN119998446A (zh) | 2022-06-07 | 2025-05-13 | 斯克里贝治疗公司 | 用于靶向pcsk9的组合物和方法 |
| EP4536819A1 (en) | 2022-06-07 | 2025-04-16 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| WO2023240157A2 (en) | 2022-06-08 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of dmd |
| WO2024206676A1 (en) | 2023-03-29 | 2024-10-03 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of lpa |
-
2021
- 2021-12-02 AU AU2021392719A patent/AU2021392719B2/en active Active
- 2021-12-02 TW TW110145073A patent/TWI922538B/zh active
- 2021-12-02 EP EP21848320.4A patent/EP4256054A1/en active Pending
- 2021-12-02 KR KR1020237022313A patent/KR20230128289A/ko active Pending
- 2021-12-02 MX MX2023006566A patent/MX2023006566A/es unknown
- 2021-12-02 PE PE2023001812A patent/PE20231178A1/es unknown
- 2021-12-02 JP JP2023533837A patent/JP7882533B2/ja active Active
- 2021-12-02 GB GB2309876.7A patent/GB2616584B/en active Active
- 2021-12-02 US US18/039,858 patent/US20240026385A1/en active Pending
- 2021-12-02 CA CA3201258A patent/CA3201258A1/en active Pending
- 2021-12-02 WO PCT/US2021/061673 patent/WO2022120095A1/en not_active Ceased
-
2022
- 2022-01-10 US US17/572,208 patent/US12163125B2/en active Active
-
2023
- 2023-06-02 CL CL2023001594A patent/CL2023001594A1/es unknown
-
2024
- 2024-05-14 US US18/663,845 patent/US20250011756A1/en active Pending
- 2024-06-11 CL CL2024001727A patent/CL2024001727A1/es unknown
- 2024-07-30 US US18/789,158 patent/US12559743B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7882533B2 (ja) | 2026-06-30 |
| US12559743B2 (en) | 2026-02-24 |
| US20230054437A1 (en) | 2023-02-23 |
| US20240376462A1 (en) | 2024-11-14 |
| US20240026385A1 (en) | 2024-01-25 |
| PE20231178A1 (es) | 2023-08-01 |
| CL2023001594A1 (es) | 2024-01-05 |
| US12163125B2 (en) | 2024-12-10 |
| GB2616584B (en) | 2026-03-04 |
| KR20230128289A (ko) | 2023-09-04 |
| CL2024001727A1 (es) | 2024-10-18 |
| WO2022120095A1 (en) | 2022-06-09 |
| AU2021392719A9 (en) | 2024-10-03 |
| GB202309876D0 (en) | 2023-08-16 |
| GB2616584A (en) | 2023-09-13 |
| AU2021392719B2 (en) | 2025-08-14 |
| CA3201258A1 (en) | 2022-06-09 |
| JP2023552374A (ja) | 2023-12-15 |
| TWI922538B (zh) | 2026-04-21 |
| EP4256054A1 (en) | 2023-10-11 |
| TW202237836A (zh) | 2022-10-01 |
| AU2021392719A1 (en) | 2023-06-22 |
| US20250011756A1 (en) | 2025-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231178A1 (es) | Sistemas crispr tipo v clase 2 disenados por ingenieria | |
| MX2022011460A (es) | Composiciones y métodos para el direccionamiento de c9orf72. | |
| CA3174139A1 (en) | Rna-editing compositions and methods of use | |
| WO2023235818A3 (en) | Engineered class 2 type v crispr systems | |
| MX2022011039A (es) | Sistemas crispr clase ii tipo v. | |
| MX2023007524A (es) | Composiciones y metodos para edicion epigenetica. | |
| MX2022012110A (es) | Sistemas crispr clase ii tipo ii. | |
| PH12022551636A1 (en) | Anti-cd73 antibodies and uses thereof | |
| PH12021550904A1 (en) | Novel crispr/cas12f enzyme and system | |
| EP4253551A3 (en) | Novel crispr dna and rna targeting enzymes and systems | |
| ZA202202628B (en) | Novel crispr dna targeting enzymes and systems | |
| PH12019502333A1 (en) | Targeted compositions | |
| EP3656873A3 (en) | Polynucleotide enrichment and amplification using argonaute systems | |
| NZ760730A (en) | Nucleic acid-guided nucleases | |
| MX2020004344A (es) | Objetivos genéticos para el direccionamiento de fijación de nitrógeno para mejorar los rasgos de las plantas. | |
| EP4361261A3 (en) | Novel cas13b orthologues crispr enzymes and systems | |
| WO2018195545A3 (en) | Variants of cpf1 (cas12a) with altered pam specificity | |
| EP3699280A3 (en) | Novel cas9 systems and methods of use | |
| MX2020011939A (es) | Nuevas enzimas y sistemas crispr. | |
| PH12020551031A1 (en) | Modified homoserine dehydrogenase and method for producing homoserine or l-amino acid derived from homoserine using the same | |
| MX2024002327A (es) | Sistemas y metodos para direccion con arn guia puntual (arngp) de adn endogeno y fuente. | |
| MX2023008629A (es) | Nuevas nucleasas modificadas y quimericas. | |
| MY193486A (en) | Novel 5 ' -inosinic acid dehydrogenase and method preparing 5'-inosinic acid using the same | |
| EP4596696A3 (en) | Compositions and methods for nucleic acid modifications | |
| MX2022006846A (es) | Conjugados y metodos para tratar la fibrosis hepatica. |